{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:07:42Z","timestamp":1789556862295,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI130473"],"award-info":[{"award-number":["R01AI130473"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sulfadoxine-pyrimethamine (SP) is the only anti-malarial drug formulation approved for intermittent preventive treatment in pregnancy (IPTp). However, mutations in the <jats:italic>Plasmodium falciparum dhfr<\/jats:italic> (<jats:italic>Pfdhfr<\/jats:italic>) and <jats:italic>dhps<\/jats:italic> (<jats:italic>Pfdhps<\/jats:italic>) genes confer resistance to pyrimethamine and sulfadoxine, respectively. Here, the frequencies of SP resistance-associated mutations from 2005 to 2018 were compared in samples from Kenyan children with malaria residing in a holoendemic transmission region.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Partial sequences of the <jats:italic>Pfdhfr<\/jats:italic> and <jats:italic>Pfdhps<\/jats:italic> genes were amplified and sequenced from samples collected in 2005 (n\u2009=\u200981), 2010 (n\u2009=\u200995), 2017 (n\u2009=\u200943), and 2018 (n\u2009=\u200955). The frequency of known mutations conferring resistance to pyrimethamine and sulfadoxine were estimated and compared. Since artemisinin-based combination therapy (ACT) is the current first-line treatment for malaria, the presence of mutations in the propeller domain of <jats:italic>P. falciparum kelch13<\/jats:italic> gene (<jats:italic>Pfk13<\/jats:italic>) linked to ACT-delayed parasite clearance was studied in the 2017\/18 samples.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among other changes, the point mutation of <jats:italic>Pfdhps<\/jats:italic> S436<jats:bold>H<\/jats:bold> increased in frequency from undetectable in 2005 to 28% in 2017\/18. Triple <jats:italic>Pfdhfr<\/jats:italic> mutant allele (C<jats:bold>IRN<\/jats:bold>I) increased in frequency from 84% in 2005 to 95% in 2017\/18, while the frequency of <jats:italic>Pfdhfr<\/jats:italic> double mutant alleles declined (allele C<jats:bold>I<\/jats:bold>C<jats:bold>N<\/jats:bold>I from 29% in 2005 to 6% in 2017\/18, and CN<jats:bold>RN<\/jats:bold>I from 9% in 2005 to undetectable in 2010 and 2017\/18). Thus, a multilocus <jats:italic>Pfdhfr<\/jats:italic>\/<jats:italic>Pfdhps<\/jats:italic> genotype with six mutations (<jats:bold>HGE<\/jats:bold>AA\/C<jats:bold>IRN<\/jats:bold>I), including <jats:italic>Pfdhps<\/jats:italic> S436<jats:bold>H<\/jats:bold>, increased in frequency from 2010 to 2017\/18. Although none of the mutations associated with ACT-delayed parasite clearance was observed, the <jats:italic>Pfk13<\/jats:italic> mutation A578S, the most widespread <jats:italic>Pfk13<\/jats:italic> SNP found in Africa, was detected in low frequency (2.04%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>There were changes in SP resistance mutant allele frequencies, including an increase in the <jats:italic>Pfdhps<\/jats:italic> S436<jats:bold>H<\/jats:bold>. Although these patterns seem consistent with directional selection due to drug pressure, there is a lack of information to determine the actual cause of such changes. These results suggest incorporating molecular surveillance of <jats:italic>Pfdhfr<\/jats:italic>\/<jats:italic>Pfdhps<\/jats:italic> mutations in the context of SP efficacy studies for intermittent preventive treatment in pregnancy (IPTp).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-020-03454-8","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T12:02:22Z","timestamp":1603368142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Changes in the frequencies of Plasmodium falciparum dhps and dhfr drug-resistant mutations in children from Western Kenya from 2005 to 2018: the rise of Pfdhps S436H"],"prefix":"10.1186","volume":"19","author":[{"given":"M. Andre\u00edna","family":"Pacheco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristan A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elly O.","family":"Munde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ndege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton","family":"Onyango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evans","family":"Raballah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel B.","family":"Anyona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collins","family":"Ouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-3430","authenticated-orcid":false,"given":"Ananias A.","family":"Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"3454_CR1","doi-asserted-by":"publisher","DOI":"10.30875\/7e6f8c91-en","volume-title":"World Malaria Report 2019","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. World Malaria Report 2019. Geneva: World Health Organization; 2019."},{"key":"3454_CR2","volume-title":"Technical expert group meeting on preventive chemotherapy: report of the technical consultation on intermittent preventive treatment in infants (IPTi)","author":"World Health Organization","year":"2009","unstructured":"World Health Organization. Technical expert group meeting on preventive chemotherapy: report of the technical consultation on intermittent preventive treatment in infants (IPTi). Geneva: World Health Organization; 2009."},{"key":"3454_CR3","volume-title":"Guidelines for the treatment of malaria","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.","edition":"3"},{"key":"3454_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1128\/CMR.17.1.235-254.2004","volume":"17","author":"AO Talisuna","year":"2004","unstructured":"Talisuna AO, Bloland P, D\u2019Alessandro U. History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev. 2004;17:235\u201354.","journal-title":"Clin Microbiol Rev"},{"key":"3454_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1124\/pr.57.1.4","volume":"57","author":"A Gregson","year":"2005","unstructured":"Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev. 2005;57:117\u201345.","journal-title":"Pharmacol Rev"},{"key":"3454_CR6","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.1073\/pnas.85.23.9114","volume":"85","author":"DS Peterson","year":"1988","unstructured":"Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA. 1988;85:9114\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3454_CR7","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/pnas.94.25.13944","volume":"94","author":"T Triglia","year":"1997","unstructured":"Triglia T, Menting JG, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci USA. 1997;94:13944\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3454_CR8","doi-asserted-by":"publisher","first-page":"12025","DOI":"10.1073\/pnas.0905922106","volume":"106","author":"ER Lozovsky","year":"2009","unstructured":"Lozovsky ER, Chookajorn T, Brown KM, Imwong M, Shaw PJ, Kamchonwongpaisan S, et al. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci USA. 2009;106:12025\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3454_CR9","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1073\/pnas.87.8.3014","volume":"87","author":"SJ Foote","year":"1990","unstructured":"Foote SJ, Galatis D, Cowman AF. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA. 1990;87:3014\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3454_CR10","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1086\/514159","volume":"176","author":"CV Plowe","year":"1997","unstructured":"Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis. 1997;176:1590\u20136.","journal-title":"J Infect Dis"},{"key":"3454_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1128\/AAC.42.1.164","volume":"42","author":"A Nzila-Mounda","year":"1998","unstructured":"Nzila-Mounda A, Mberu EK, Sibley CH, Plowe CV, Winstanley PA, Watkins WM. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob Agents Chemother. 1998;42:164\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"3454_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1086\/338566","volume":"185","author":"JG Kublin","year":"2002","unstructured":"Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185:380\u20138.","journal-title":"J Infect Dis"},{"key":"3454_CR13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/1475-2875-13-250","volume":"13","author":"DW Juma","year":"2014","unstructured":"Juma DW, Omondi AA, Ingasia L, Opot B, Cheruiyot A, Yeda R, et al. Trends in drug resistance codons in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Kenyan parasites from 2008 to 2012. Malar J. 2014;13:250.","journal-title":"Malar J"},{"key":"3454_CR14","volume-title":"Artemisinin and artemisinin-based combination therapy resistance: status report","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Artemisinin and artemisinin-based combination therapy resistance: status report. Geneva: World Health Organization; 2017."},{"key":"3454_CR15","doi-asserted-by":"publisher","first-page":"e942","DOI":"10.1016\/S2214-109X(20)30119-4","volume":"8","author":"ME Roh","year":"2020","unstructured":"Roh ME, Kuile FOT, Rerolle F, Glymour MM, Shiboski S, Gosling R, et al. Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine on birthweight: a mediation analysis. Lancet Glob Health. 2020;8:e942\u201353.","journal-title":"Lancet Glob Health"},{"key":"3454_CR16","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1001\/jama.297.23.2603","volume":"297","author":"FO ter Kuile","year":"2007","unstructured":"ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA. 2007;297:2603\u201316.","journal-title":"JAMA"},{"key":"3454_CR17","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/j.1365-3156.2009.02303.x","volume":"14","author":"RD Gosling","year":"2009","unstructured":"Gosling RD, Carneiro I, Chandramohan D. Intermittent preventive treatment of malaria in infants: how does it work and where will it work? Trop Med Int Health. 2009;14:1003\u201310.","journal-title":"Trop Med Int Health"},{"key":"3454_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.pt.2013.08.002","volume":"29","author":"I Naidoo","year":"2013","unstructured":"Naidoo I, Roper C. Mapping \u201cpartially resistant\u201d, \u201cfully resistant\u201d, and \u201csuper resistant\u201d malaria. Trends Parasitol. 2013;29:505\u201315.","journal-title":"Trends Parasitol"},{"key":"3454_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1475-2875-11-134","volume":"11","author":"NC Iriemenam","year":"2012","unstructured":"Iriemenam NC, Shah M, Gatei W, van Eijk AM, Ayisi J, Kariuki S, et al. Temporal trends of sulfadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Malar J. 2012;11:134.","journal-title":"Malar J"},{"key":"3454_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1207-3","author":"WWARN K13 Genotype-Phenotype Study Group","year":"2019","unstructured":"WWARN K13 Genotype-Phenotype Study Group. Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments-a WWARN individual patient data meta-analysis. BMC Med. 2019. https:\/\/doi.org\/10.1186\/s12916-018-1207-3.","journal-title":"BMC Med"},{"key":"3454_CR21","doi-asserted-by":"publisher","first-page":"376","DOI":"10.4269\/ajtmh.2006.74.376","volume":"74","author":"JM Ong'echa","year":"2006","unstructured":"Ong\u2019echa JM, Keller CC, Were T, Ouma C, Otieno RO, Landis-Lewis Z, et al. Parasitemia, anemia, and malarial anemia in infants and young children in a rural holoendemic Plasmodium falciparum transmission area. Am J Trop Med Hyg. 2006;74:376\u201385.","journal-title":"Am J Trop Med Hyg"},{"key":"3454_CR22","doi-asserted-by":"publisher","first-page":"e02550","DOI":"10.1128\/AAC.02550-18","volume":"63","author":"MA Pacheco","year":"2019","unstructured":"Pacheco MA, Kadakia ER, Chaudhary Z, Perkins DJ, Kelley J, Ravishankar S, et al. Evolution and genetic diversity of the k13 gene associated with artemisinin delayed parasite clearance in Plasmodium falciparum. Antimicrob Agents Chemother. 2019;63:e02550-e2618.","journal-title":"Antimicrob Agents Chemother"},{"key":"3454_CR23","doi-asserted-by":"publisher","first-page":"e105690","DOI":"10.1371\/journal.pone.0105690","volume":"9","author":"MD Conrad","year":"2014","unstructured":"Conrad MD, Bigira V, Kapisi J, Muhindo M, Kamya MR, Havlir DV, et al. Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are notprevalent in Plasmodium falciparum isolated from Ugandan children. PLoS ONE. 2014;9:e105690.","journal-title":"PLoS ONE"},{"key":"3454_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4269\/ajtmh.15-0005","volume":"93","author":"AA Escalante","year":"2015","unstructured":"Escalante AA, Ferreira MU, Vinetz JM, Volkman SK, Cui L, Gamboa D, et al. Malaria molecular epidemiology: lessons from the international centers of excellence for Malaria Research Network. Am J Trop Med Hyg. 2015;93:79\u201386.","journal-title":"Am J Trop Med Hyg"},{"key":"3454_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12936-019-2784-0","volume":"18","author":"R Dalmat","year":"2019","unstructured":"Dalmat R, Naughton B, Kwan-Gett TS, Slyker J, Stuckey EM. Use cases for genetic epidemiology in malaria elimination. Malar J. 2019;18:163.","journal-title":"Malar J"},{"key":"3454_CR26","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1128\/microbiolspec.AME-0010-2019","volume":"7","author":"AA Escalante","year":"2019","unstructured":"Escalante AA, Pacheco MA. Malaria molecular epidemiology: An evolutionary genetics perspective. Microbiol Spectr. 2019;7:1128.","journal-title":"Microbiol Spectr"},{"key":"3454_CR27","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1046\/j.1365-3156.2000.00643.x","volume":"5","author":"R Shretta","year":"2000","unstructured":"Shretta R, Omumbo J, Rapuoda B, Snow RW. Using evidence to change anti-malarial drug policy in Kenya. Trop Med Int Health. 2000;5:755\u201364.","journal-title":"Trop Med Int Health"},{"key":"3454_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1475-2875-11-77","volume":"11","author":"AM McCollum","year":"2012","unstructured":"McCollum AM, Schneider KA, Griffing SM, Zhou Z, Kariuki S, Ter-Kuile F, et al. Differences in selective pressure on dhps and dhfr drug resistant mutations in western Kenya. Malar J. 2012;11:77.","journal-title":"Malar J"},{"key":"3454_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1475-2875-6-72","volume":"6","author":"AA Amin","year":"2007","unstructured":"Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, et al. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J. 2007;6:72.","journal-title":"Malar J"},{"key":"3454_CR30","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/1475-2875-9-338","volume":"9","author":"MD Spalding","year":"2010","unstructured":"Spalding MD, Eyase FL, Akala HM, Bedno SA, Prigge ST, Coldren RL, et al. Increased prevalence of the pfdhfr\/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu. Kenya Malar J. 2010;9:338.","journal-title":"Kenya Malar J"},{"key":"3454_CR31","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/infdis\/jiv078","volume":"212","author":"E Artimovich","year":"2015","unstructured":"Artimovich E, Schneider K, Taylor TE, Kublin JG, Dzinjalamala FK, Escalante AA, et al. Persistence of sulfadoxine-pyrimethamine resistance despite reduction of drug pressure in Malawi. J Infect Dis. 2015;212:694\u2013701.","journal-title":"J Infect Dis"},{"key":"3454_CR32","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1128\/AAC.00975-07","volume":"52","author":"Z Zhou","year":"2008","unstructured":"Zhou Z, Griffing SM, de Oliveira AM, McCollum AM, Quezada WM, Arrospide N, et al. Decline in sulfadoxine-pyrimethamine-resistant alleles after change in drug policy in the Amazon region of Peru. Antimicrob Agents Chemother. 2008;52:739\u201341.","journal-title":"Antimicrob Agents Chemother"},{"key":"3454_CR33","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12936-020-03247-z","volume":"19","author":"MA Pacheco","year":"2020","unstructured":"Pacheco MA, Forero-Pe\u00f1a DA, Schneider KA, Chavero M, Gamardo A, Figuera L, et al. Malaria in Venezuela: changes in the complexity of infection reflects the increment in transmission intensity. Malar J. 2020;19:176.","journal-title":"Malar J"},{"key":"3454_CR34","unstructured":"Maternal and Child Survival Program, USAID from American People. 2020. https:\/\/www.mcsprogram.org\/. Accessed 05 Oct 2020."},{"key":"3454_CR35","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S0140-6736(01)06201-8","volume":"358","author":"JK Iyer","year":"2001","unstructured":"Iyer JK, Milhous WK, Cortese JF, Kublin JG, Plowe CV. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet. 2001;358:1066\u20137.","journal-title":"Lancet"},{"key":"3454_CR36","doi-asserted-by":"publisher","first-page":"586","DOI":"10.4269\/ajtmh.2003.68.586","volume":"68","author":"I Khalil","year":"2003","unstructured":"Khalil I, Ronn AM, Alifrangis M, Gabar HA, Satti GM, Bygbjerg IC. Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum topyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole. Am J Trop Med Hyg. 2003;68:586\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"3454_CR37","doi-asserted-by":"publisher","first-page":"e0007223","DOI":"10.1371\/journal.pntd.0007223","volume":"13","author":"DW Juma","year":"2009","unstructured":"Juma DW, Muiruri P, Yuhas K, John-Stewart G, Ottichilo R, Waitumbi J, et al. The prevalence and antifolate drug resistance profiles of Plasmodium falciparum in study participants randomized to discontinue or continue cotrimoxazole prophylaxis. PLoS Negl Trop Dis. 2009;13:e0007223.","journal-title":"PLoS Negl Trop Dis"},{"key":"3454_CR38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1086\/504687","volume":"194","author":"AM McCollum","year":"2006","unstructured":"McCollum AM, Poe AC, Hamel M, Huber C, Zhou Z, Shi YP, et al. Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. J Infect Dis. 2006;194:189\u201397.","journal-title":"J Infect Dis"},{"key":"3454_CR39","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.4269\/ajtmh.2005.73.1131","volume":"73","author":"T Gebru-Woldearegai","year":"2005","unstructured":"Gebru-Woldearegai T, Hailu A, Grobusch MP, Kun JFJ. Molecular surveillance of mutations in dihydrofolate reductase and dihydropterate synthase genes of Plasmodium falciparum in Ethiopia. Am J Trop Med Hyg. 2005;73:1131\u20134.","journal-title":"Am J Trop Med Hyg"},{"key":"3454_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12936-015-0588-4","volume":"14","author":"M Shah","year":"2015","unstructured":"Shah M, Omosun Y, Lal A, Odero C, Gatei W, Otieno K, et al. Assessment of molecular markers for anti-malarial drug resistance after the introduction and scale-up of malaria control interventions in western Kenya. Malar J. 2015;14:75.","journal-title":"Malar J"},{"key":"3454_CR41","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12936-015-0723-2","volume":"14","author":"A Heuchert","year":"2015","unstructured":"Heuchert A, Abduselam N, Zeynudin A, Eshetu T, L\u00f6scher T, Wieser A, et al. Molecular markers of anti-malarial drug resistance in southwest Ethiopia over time: regional surveillance from 2006 to 2013. Malar J. 2015;14:208.","journal-title":"Malar J"},{"key":"3454_CR42","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1046\/j.1365-3156.2000.00632.x","volume":"5","author":"S Biswas","year":"2000","unstructured":"Biswas S, Escalante A, Chaiyaroj S, Angkasekwinai P, Lal AA. Prevalence of point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from India and Thailand: a molecular epidemiologic study. Trop Med Int Health. 2000;5:737\u201343.","journal-title":"Trop Med Int Health"},{"key":"3454_CR43","doi-asserted-by":"publisher","first-page":"e1000830","DOI":"10.1371\/journal.ppat.1000830","volume":"6","author":"S Vinayak","year":"2010","unstructured":"Vinayak S, Alam MT, Mixson-Hayden T, McCollum AM, Sem R, Shah NK, et al. Origin and evolution of sulfadoxine resistant Plasmodium falciparum. PLoS Pathog. 2010;6:e1000830.","journal-title":"PLoS Pathog"},{"key":"3454_CR44","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3201\/eid2103.140898","volume":"21","author":"R Isozumi","year":"2015","unstructured":"Isozumi R, Uemura H, Kimata I, Ichinose Y, Logedi J, Omar AH, et al. Novel mutations in K13 propeller gene of artemisinin-resistant Plasmodium falciparum. Emerg Infect Dis. 2015;21:490\u20132.","journal-title":"Emerg Infect Dis"},{"key":"3454_CR45","first-page":"1352","volume":"211","author":"E Kamau","year":"2015","unstructured":"Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. J Infect Dis. 2015;211:1352\u20135.","journal-title":"J Infect Dis"},{"key":"3454_CR46","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.4269\/ajtmh.14-0605","volume":"92","author":"A Ouattara","year":"2015","unstructured":"Ouattara A, Kone A, Adams M, Fofana B, Maiga AW, Hampton S, et al. Polymorphisms in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara. Mali Am J Trop Med Hyg. 2015;92:1202\u20136.","journal-title":"Mali Am J Trop Med Hyg"},{"key":"3454_CR47","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/infdis\/jiu467","volume":"211","author":"SM Taylor","year":"2015","unstructured":"Taylor SM, Parobek CM, DeConti DK, Kayentao K, Coulibaly SO, Greenwood BM, et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis. 2015;211:680\u20138.","journal-title":"J Infect Dis"},{"key":"3454_CR48","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.4269\/ajtmh.17-0505","volume":"98","author":"ZR de Laurent","year":"2018","unstructured":"de Laurent ZR, Chebon LJ, Ingasia LA, Akala HM, Andagalu B, Ochola-Oyier LI, et al. Polymorphisms in the K13 gene in Plasmodium falciparum from different malaria transmission areas of Kenya. Am J Trop Med Hyg. 2018;98:1360\u20136.","journal-title":"Am J Trop Med Hyg"},{"key":"3454_CR49","doi-asserted-by":"publisher","first-page":"e01067","DOI":"10.1128\/AAC.01067-19","volume":"63","author":"K Wamae","year":"2019","unstructured":"Wamae K, Okanda D, Ndwiga L, Osoti V, Kimenyi KM, Abdi AI, et al. No evidence of P. falciparum K13 artemisinin conferring mutations over a 24-year analysis in Coastal Kenya, but a near complete reversion to chloroquine wild type parasites. Antimicrob Agents Chemother. 2019;63:e01067-e1119.","journal-title":"Antimicrob Agents Chemother"},{"key":"3454_CR50","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12936-016-1095-y","volume":"15","author":"J Muwanguzi","year":"2016","unstructured":"Muwanguzi J, Henriques G, Sawa P, Bousema T, Sutherland CJ, Beshir KB. Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children. Malar J. 2016;15:36.","journal-title":"Malar J"},{"key":"3454_CR51","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12879-016-1777-7","volume":"16","author":"M Ocan","year":"2016","unstructured":"Ocan M, Bwanga F, Okeng A, Katabazi F, Kigozi E, Kyobe S, et al. Prevalence of K13-propeller gene polymorphisms among Plasmodium falciparum parasites isolated from adult symptomatic patients in northern Uganda. BMC Infect Dis. 2016;16:428.","journal-title":"BMC Infect Dis"},{"key":"3454_CR52","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMc1612765","volume":"376","author":"F Lu","year":"2017","unstructured":"Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H, et al. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med. 2017;376:991\u20133.","journal-title":"N Engl J Med"},{"key":"3454_CR53","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/1475-2875-13-431","volume":"13","author":"A Mohon","year":"2014","unstructured":"Mohon A, Alam M, Bayih A, Folefoc A, Shahinas D, Haque R, et al. Mutations in 386 Plasmodium falciparum K13 propeller gene from Bangladesh (2009\u20132013). Malar J. 2014;13:431.","journal-title":"Malar J"},{"key":"3454_CR54","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12936-020-3140-0","volume":"19","author":"X Wang","year":"2020","unstructured":"Wang X, Ruan W, Zhou S, Huang F, Lu Q, Feng X, et al. Molecular surveillance of Pfcrt and k13 propeller polymorphisms of imported Plasmodium falciparum cases to Zhejiang Province, China between 2016 and 2018. Malar J. 2020;19:59.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03454-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-020-03454-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03454-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T23:06:59Z","timestamp":1634857619000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-020-03454-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3454"],"URL":"https:\/\/doi.org\/10.1186\/s12936-020-03454-8","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"13 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee of the Kenya Medical Research Institute, the University of New Mexico Institutional Review Board, the Los Alamos National Laboratory (LANL) Institutional Review Board and the Maseno University Ethics Review Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"378"}}